DOI QR코드

DOI QR Code

Effects of Spinal-Z in Patients with Gastroesophageal Cancer

  • Panahi, Yunes (Baqiyatallah University of Medical Sciences) ;
  • Saadat, Alireza (Baqiyatallah University of Medical Sciences) ;
  • Seifi, Maghsoud (Baqiyatallah University of Medical Sciences) ;
  • Rajaee, Mahdi (Gastrointestinal Pharmacology Interest Group (GPIG), Universal Scientific Education and Research Network (USERN)) ;
  • Butler, Alexandra E. (Life Sciences Research Division, Anti-Doping Laboratory Qatar) ;
  • Sahebkar, Amirhossein (Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences)
  • Received : 2017.09.26
  • Accepted : 2018.03.02
  • Published : 2018.03.31

Abstract

Objective: The purpose of this study was to investigate the efficacy and safety of spinal-Z, derived from Peganum harmala seeds and Dracocephalum Kotschyi Boiss leaves, in patients with esophageal and stomach adenocarcinoma, and squamous cell carcinoma of the esophagus. Methods: Sixty-one patients with malignancies of the upper gastrointestinal tract were randomly assigned to one of two groups (treatment or control) in a double-blind fashion. Six capsules of Spinal-Z were prescribed to the patients with the regimen of 600 mg/m2/day, and placebo to the control group, for six months. Results: There were no significant differences between the two groups with regard to age, sex, duration of cancer, type of cancer and family history of cancer. There were significant differences in abdominal pain, heartburn, constipation and vomiting between the two groups, following spinal-Z therapy. Evaluation of drug side effects showed no difference in cough or other respiratory symptoms, itching, headache or dizziness between the two groups, both before and after treatment. Conclusion: This study indicates that Spinal-Z is safe and efficacious in the management of patients with upper gastrointestinal tract cancers.

References

  1. Tepes B. Can gastric cancer be prevented? J Physiol Pharmacol. 2009;60(Suppl 7):71-7.
  2. Yang G, Li X, Li X, Wang L, Li J, Song X, et al. Traditional chinese medicine in cancer care: a review of case series published in the chinese literature. Evid Based Complement Alternat Med. 2012;2012:751046.
  3. Qi F, Li A, Inagaki Y, Gao J, Li J, Kokudo N, et al. Chinese herbal medicines as adjuvant treatment during chemo- or radio-therapy for cancer. Biosci Trends. 2010;4(6):297-307.
  4. Toledo AL, Koifman RJ, Koifman S, Marchioni DM. Dietary patterns and risk of oral and pharyngeal cancer: a case-control study in Rio de Janeiro, Brazil. Cad Saude Publica. 2010;26(1):135- 42. https://doi.org/10.1590/S0102-311X2010000100014
  5. Iranshahi M, Sahebkar A, Hosseini ST, Takasaki M, Konoshima T, Tokuda H. Cancer chemopreventive activity of diversin from Ferula diversivittata in vitro and in vivo. Phytomedicine. 2010;17(3-4):269-73. https://doi.org/10.1016/j.phymed.2009.05.020
  6. Iranshahi M, Sahebkar A, Takasaki M, Konoshima T, Tokuda H. Cancer chemopreventive activity of the prenylated coumarin, umbelliprenin, in vivo. Eur J Cancer Prev. 2009;18(5):412-5. https://doi.org/10.1097/CEJ.0b013e32832c389e
  7. Mirzaei H, Naseri G, Rezaee R, Mohammadi M, Banikazemi Z, Mirzaei HR, et al. Curcumin: A new candidate for melanoma therapy? Int J Cancer. 2016;139(8):1683-95. https://doi.org/10.1002/ijc.30224
  8. Momtazi AA, Shahabipour F, Khatibi S, Johnston TP, Pirro M, Sahebkar A. Curcumin as a MicroRNA regulator in cancer: A review. Rev. Physiol Biochem Pharmacol. 2016;171:1-38.
  9. Shahabipour F, Caraglia M, Majeed M, Derosa G, Maffioli P, Sahebkar A. Naturally occurring anti-cancer agents targeting EZH2. Cancer Lett. 2017;400:325-35. https://doi.org/10.1016/j.canlet.2017.03.020
  10. Shakeri A, Sahebkar A. Anti-cancer products from marine sponges: Progress and promise. Recent Patents on Drug Delivery and Formulation. 2015;9(3):187-8. https://doi.org/10.2174/1872211309666150529131549
  11. Teymouri M, Pirro M, Johnston TP, Sahebkar A. Curcumin as a multifaceted compound against human papilloma virus infection and cervical cancers: A review of chemistry, cellular, molecular, and preclinical features. BioFactors. 2017;43(3):331-346. https://doi.org/10.1002/biof.1344
  12. Jahaniani F, Ebrahimi SA, Rahbar-Roshandel N, Mahmoudian M. Xanthomicrol is the main cytotoxic component of Dracocephalum kotschyii and a potential anti-cancer agent. Phytochemistry. 2005;66(13):1581-92. https://doi.org/10.1016/j.phytochem.2005.04.035
  13. Murphy AG, Lynch D, Kelly RJ. State of the art management of metastatic gastroesophageal cancer. Ann Transl Med. 2015;3(16):236.
  14. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86. https://doi.org/10.1002/ijc.29210
  15. Simsa J, Leffler J, Hoch J, Linke Z, Padr R. Gastric cancer in young patients - is there any hope for them? Acta Chir Belg. 2004;104(6):673-6. https://doi.org/10.1080/00015458.2004.11679641
  16. Ahmadlou N, Omidvari, SH, Mosalaei A. Results of Post-operative Radiotherapy in Patients withHigh Risk Gastric Cancer. J Med Res. 2003;1(3):43-9.
  17. Cordell GA, Beecher CW, Pezzuto JM. Can ethnopharmacology contribute to the development of new anticancer drugs? J Ethnopharmacol. 1991;32(1-3):117-33. https://doi.org/10.1016/0378-8741(91)90110-Y
  18. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997;15(1):261-7. https://doi.org/10.1200/JCO.1997.15.1.261
  19. Wang J, Xu R, Li J, Bai Y, Liu T, Jiao S, et al. Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer. Gastric Cancer. 2016;19(1):234- 44. https://doi.org/10.1007/s10120-015-0457-4
  20. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24(31):4991-7. https://doi.org/10.1200/JCO.2006.06.8429
  21. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol. 2007;25(22):3205-9. https://doi.org/10.1200/JCO.2006.10.4968
  22. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol. 2007;25(22):3210-6. https://doi.org/10.1200/JCO.2006.08.3956
  23. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26(9):1435-42. https://doi.org/10.1200/JCO.2007.13.9378
  24. Bouche O, Raoul JL, Bonnetain F, Giovannini M, Etienne PL, Lledo G, et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803. J Clin Oncol. 2004;22(21):4319-28. https://doi.org/10.1200/JCO.2004.01.140
  25. van Meerten E, Eskens FA, van Gameren EC, Doorn L, van der Gaast A. First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study. Br J Cancer. 2007;96(9):1348-52. https://doi.org/10.1038/sj.bjc.6603750
  26. Moehler M, Kanzler S, Geissler M, Raedle J, Ebert MP, Daum S, et al. A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2010;21(1):71-7. https://doi.org/10.1093/annonc/mdp269
  27. Hong YS, Song SY, Lee SI, Chung HC, Choi SH, Noh SH, et al. A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann Oncol. 2004;15(9):1344-7. https://doi.org/10.1093/annonc/mdh343
  28. Prithviraj GK, Baksh K, Fulp W, Meredith K, Hoffe S, Shridhar R, et al. Carboplatin and paclitaxel as first-line treatment of unresectable or metastatic esophageal or gastric cancer. Dis Esophagus. 2015;28(8):782-7. https://doi.org/10.1111/dote.12279
  29. Petrelli F, Zaniboni A, Coinu A, Cabiddu M, Ghilardi M, Sqroi G et al. Cisplatin or Not in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis. PLoS ONE. 2013;8(12):e83022. https://doi.org/10.1371/journal.pone.0083022
  30. Wohrer SS, Raderer M, Hejna M. Palliative chemotherapy for advanced gastric cancer. Ann Oncol. 2004;15(11):1585-95. https://doi.org/10.1093/annonc/mdh422
  31. Rezvani H, Attarian H, Ghadyani M, Abasahl A. Eloxatin (Oxaliplatin), Xeloda (Capecitabine) and Epirubicin (EXE) as First Line Treatment in Metastatic Gastric Carcinoma. Iranian Journal of Surgery. 2008;16(3):26-33.
  32. Seilanian Toosi M, Aledavood SA, Anvari K, Nowferesti G, Mohtashami S. The treatment outcome of definitive chemoradiotherapy in patients with esophageal squamous cell carcinoma. Journal of Gorgan University of Medical Sciences. 2007;9(3):22-9.
  33. Yazdanbod A, Sadeghifard, N., Niknam, M. Therapeutic effects, adverse events and Spinal-z pharmaceutical indicators in the treatment of cancer of the upper gastrointestinal tract Ardebil. Iran: Ardebil University of Medical Sciences; 2001.
  34. Shoaib M, Shah SW, Ali N, Shah I, Ullah S, Ghias M, et al. Scientific investigation of crude alkaloids from medicinal plants for the management of pain. BMC Complement Altern Med. 2016;16(1):178. https://doi.org/10.1186/s12906-016-1157-2
  35. Hamsa TP, Kuttan G. Harmine inhibits tumour specific neo-vessel formation by regulating VEGF, MMP, TIMP and pro-inflammatory mediators both in vivo and in vitro. Eur J Pharmacol. 2010;649(1-3):64-73. https://doi.org/10.1016/j.ejphar.2010.09.010
  36. Lamchouri F, Zemzami M, Jossang A, Abdellatif A, Israili ZH, Lyoussi B. Cytotoxicity of alkaloids isolated from Peganum harmala seeds. Pak J Pharm Sci. 2013;26(4):699-706.
  37. Sobhani AM, Ebrahimi SA, Mahmoudian M. An in vitro evaluation of human DNA topoisomerase I inhibition by Peganum harmala L. seeds extract and its beta-carboline alkaloids. J Pharm Pharm Sci. 2002;5(1):19-23.
  38. Soliman AM, Abu-El-Zahab HS, Alswiai GA. Efficacy evaluation of the protein isolated from Peganum harmala seeds as an antioxidant in liver of rats. Asian Pac J Med. 2013;6(4):285-95. https://doi.org/10.1016/S1995-7645(13)60058-9
  39. Pisoschi AM, Pop A, Cimpeanu C, Predoi G. Antioxidant Capacity Determination in Plants and Plant-Derived Products: A Review. Oxid Med Cell Longev. 2016;2016:9130976.
  40. Herraiz T, Gonzalez D, Ancin-Azpilicueta C, Aran VJ, Guillen H. beta-Carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO). Food Chem Toxicol. 2010;48(3):839-45. https://doi.org/10.1016/j.fct.2009.12.019